- •
Growth hormone (GH) treatment effectively induces catch-up growth and improves adult height in most short children born small for gestational age (SGA).
- •
During GH treatment, fat mass, insulin sensitivity, and blood pressure decrease, whereas lean body mass increases; favorable changes occur in lipid levels.
- •
GH-induced lower insulin sensitivity is reversible after GH treatment and 6.5 years thereafter it is similar in GH-treated and untreated short SGA adolescents.
- •
At 6.5 years after GH treatment,
Growth and Metabolism in Children Born Small for Gestational Age
Section snippets
Key points
Small for gestational age
Small for gestational age (SGA) accounts for approximately 20% of all cases of short stature.2 SGA refers to the size of an infant at birth. It is defined as a birth length and/or weight of at least 2 standard deviation scores (SDS) below the mean for gestational age and gender.3 The etiology of SGA consists of a broad spectrum of maternal, environmental, placental, and fetal factors, but in a significant proportion of cases the reason for being born SGA remains unclear. By definition, 2.3% of
Effects of growth hormone treatment in children born small for gestational age
An overview of the main effects of GH treatment is shown in Table 2.
Metabolic and endocrine consequences in adults born small for gestational age
Low birth weight is associated with metabolic and cardiovascular adult diseases in late adulthood.30, 31
Combining growth hormone treatment with gonadotropin-releasing hormone analog treatment
Data have shown that children born SGA with an expected AH less than −2 SDS at start of puberty can benefit from additional GnRHa treatment to delay puberty for 2 years.11 Recently, it has been shown that combined GH/GnRHa treatment results in a similar body composition, insulin sensitivity, blood pressure, and lipid levels at AH as treatment with GH only.42, 43 Additional GnRHa treatment for 2 years can therefore be considered in pubertal SGA children with a poor AH expectation.
Summary
Short stature is one of the most common conditions presented to pediatric endocrinologists. SGA accounts for approximately 20% of all cases of short stature. Most children born SGA show spontaneous catch-up growth to a normal weight and height above −2 SDS; however, 10% remain short and can be treated with GH to improve AH. GH treatment is effective in inducing catch-up growth and improving AH. It also has positive effects on several risk factors for type 2 diabetes and cardiovascular disease.
References (43)
Fetal programming of the growth hormone-insulin-like growth factor axis
Trends Endocrinol Metab
(2002)- et al.
Reduced insulin sensitivity during growth hormone therapy for short children born small for gestational age
J Pediatr
(2003) - et al.
Weight in infancy and death from ischaemic heart disease
Lancet
(1989) - et al.
Growth in full-term small-for-gestational-age infants: from birth to final height
Pediatr Res
(1995) - et al.
International Small for Gestational Age Advisory Board consensus development conference statement: management of short children born small for gestational age, April 24-October 1, 2001
Pediatrics
(2003) - et al.
Children born small for gestational age: do they catch up?
Pediatr Res
(1995) - et al.
Children born small-for-gestational age: postnatal growth and hormonal status
Horm Res
(1998) - et al.
Spontaneous 24-hour growth hormone profiles in prepubertal small for gestational age children
J Clin Endocrinol Metab
(1995) - et al.
Endogenous and stimulated GH secretion, urinary GH excretion, and plasma IGF-I and IGF-II levels in prepubertal children with short stature after intrauterine growth retardation. The Dutch Working Group on Growth Hormone
Clin Endocrinol
(1994) - et al.
Physiological growth hormone secretion and response to growth hormone treatment in children with short stature and intrauterine growth retardation
Acta Paediatr Scand Suppl
(1989)
Improvement in adult height after growth hormone treatment in adolescents with short stature born small for gestational age: results of a randomized controlled study
J Clin Endocrinol Metab
Final height in short children born small for gestational age treated with growth hormone
Pediatr Res
Adult height in short children born SGA treated with growth hormone and gonadotropin releasing hormone analog: results of a randomized, dose-response GH trial
J Clin Endocrinol Metab
Adult height after long-term, continuous growth hormone (GH) treatment in short children born small for gestational age: results of a randomized, double-blind, dose-response GH trial
J Clin Endocrinol Metab
Risk factors for diabetes mellitus type 2 and metabolic syndrome are comparable for previously growth hormone-treated young adults born small for gestational age (SGA) and untreated short SGA controls
J Clin Endocrinol Metab
Impact of growth hormone therapy on adult height of children born small for gestational age
Pediatrics
Prediction model for adult height of small for gestational age children at the start of growth hormone treatment
J Clin Endocrinol Metab
Does preterm birth influence the response to growth hormone treatment in short, small for gestational age children?
Clin Endocrinol
Final height data, body composition and glucose metabolism in growth hormone-treated short children born small for gestational age
Horm Res
The effect of growth hormone treatment on metabolic and cardiovascular risk factors is similar in preterm and term short, small for gestational age children
Clin Endocrinol
Impact of growth hormone status on body composition and the skeleton
Horm Res
Cited by (24)
Pediatric disorders of stature
2023, Encyclopedia of Child and Adolescent Health, First EditionGrowth outcome at 2 years using Fenton and Intergrowth-21st charts in infants less than 1500 g
2022, Anales de PediatriaAssociation of exposure to fine particulate matter wave over the preconception and pregnancy periods with adverse birth outcomes: Results from the project ELEFANT
2022, Environmental ResearchCitation Excerpt :A majority of previous studies have reported that maternal exposure to ambient air pollution around pregnancy was associated with increased risks of adverse birth outcomes, such as stillbirth, preterm birth (PTB), small for gestational age (SGA), low birth weight (LBW) and large for gestational age (LGA) (Chen et al., 2020; Melody et al., 2020; Yuan et al., 2019; Zhao et al., 2018). Adverse birth outcomes can not only have a severe impact on the normal development of childhood but also increase risks of diabetes, cardiovascular disease, chronic respiratory disease, metabolic system disease and neurobehavioral problems in adulthood, imposing a huge economic burden on society (Aarnoudse-Moens et al., 2009; Caudri et al., 2007; Levine et al., 2015; Norman and M, 2013; Rundle et al., 2012; Saigal and Doyle, 2008; Trasande et al., 2016; van der Steen and Hokken-Koelega, 2016). However, to the best of our knowledge, no study has explored the durational effects of sustained maternal exposure to high-level air pollution on adverse birth outcomes, though increasing epidemiological studies demonstrated that single days of high ambient air pollution could increase risks of adverse birth outcomes (Guo et al., 2019; Li et al., 2019).
Genetic causes of proportionate short stature
2018, Best Practice and Research: Clinical Endocrinology and MetabolismCitation Excerpt :If this treatment produces antibodies against GH arresting growth, rhIGF1 could be employed. In children born Small for Gestational Age that remain short, rhGH improves adult height [87,88]. Furthermore, some children with Silver-Russell syndrome have also been treated with rhGH, with good results [17].
Short children born small for gestational age outcomes in the era of growth hormone therapy
2018, Growth Hormone and IGF ResearchCitation Excerpt :When corrected for mid-parental target height the overall height gains were slightly less: 1.46 SDS (9.2 cm) in those children born SGA and treated with rhGH and 0.4 SDS (2.5 cm) compared to those who did not receive rhGH therapy. In addition to promoting longitudinal growth, rhGH treatment of short children born SGA also favorably affects body composition, blood pressure and lipid metabolism [67–69]. Several factors are associated with GH response including age and height at start of therapy, mid-parental height and dose [10].
Disclosure Statement: A.C.S. Hokken-Koelega received unrestricted research grants from Novo Nordisk and Pfizer for investigator initiated growth hormone studies in short children born SGA. M. van der Steen has nothing to disclose.